$30.79
0.07%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US92243G1085
Symbol
PCVX

Vaxcyte Inc Stock price

$30.79
-3.89 11.22% 1M
-42.23 57.83% 6M
-51.07 62.39% YTD
-48.49 61.16% 1Y
+2.89 10.36% 3Y
-14.49 32.00% 5Y
+4.64 17.74% 10Y
+4.64 17.74% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.02 0.07%
ISIN
US92243G1085
Symbol
PCVX
Industry

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$2.3b
Net debt
positive
Cash
$1.7b
Shares outstanding
129.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
94.2%
Return on Equity
-14.0%
ROCE
-22.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-685.8m | $-667.1m
EBIT
$-709.1m | $-754.6m
Net Income
$-547.5m | $-647.0m
Free Cash Flow
$-563.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-19.7% | -20.5%
EBIT
-23.0% | -32.5%
Net Income
-10.1% | -39.5%
Free Cash Flow
3.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.0
FCF per Share
$-4.3
Short interest
9.9%
Employees
414
Rev per Employee
$0.0
Show more

Is Vaxcyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Vaxcyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Vaxcyte Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Vaxcyte Inc forecast:

Buy
93%
Hold
7%

Financial data from Vaxcyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 116 116
57% 57%
-
- Research and Development Expense 593 593
39% 39%
-
-686 -686
20% 20%
-
- Depreciation and Amortization 23 23
477% 477%
-
EBIT (Operating Income) EBIT -709 -709
23% 23%
-
Net Profit -548 -548
10% 10%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vaxcyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxcyte Inc Stock News

Neutral
The Motley Fool
27 days ago
Vaxcyte (PCVX) Q2 Loss Widens 11%
Neutral
GlobeNewsWire
27 days ago
Following Interactions with FDA on VAX-31 Adult Program, Including End-of-Phase 2 Meeting, Company Finalizing Phase 3 Clinical Program to Validate VAX-31 as Potential New Standard-of-Care Adult PCV ; Pivotal, Non-Inferiority Study Expected to be Initiated in Fourth Quarter of 2025 with Topline Data in 2026 FDA Provided Input on VAX-31 Adult CMC Licensure Requirements Facilitating Progression to...
Neutral
GlobeNewsWire
4 months ago
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Compl...
More Vaxcyte Inc News

Company Profile

Vaxcyte, Inc., a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is headquartered in Foster City, California.

Head office United States
CEO Grant Pickering
Employees 414
Founded 2013
Website vaxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today